Although they offer an alternative to warfarin for preventing stroke in patients with atrial fibrillation, effective use of the new anticoagulants requires careful patient selection.
The ACC/AHA cholesterol guideline can be a powerful tool for making multifactorial measures of cardiovascular disease risk assessment, particularly in African American populations, but clinicians should be aware of its limitations.
Study results presented at ACC.14 show treatment with PCSK9 inhibitor evolocumab significantly reduces LDL-cholesterol levels in patients with hypercholesterolemia.
Collaboration between American Heart Association, American College of Cardiology, Heart Rhythm Society, and the Society of Thoracic Surgery includes guidance on the use of new oral anticoagulants.
In light of the fact that many physicians continue to rely on observational analysis and patient self-reporting to monitor opioid addiction or misuse, results from a scientific poster reinforced the benefits of routine urine drug testing in improving compliance with prescribed opioid medications and ultimately enhancing pain care.
For adults at high cardiovascular risk with impaired glucose tolerance, baseline and change in objectively-assessed ambulatory activity are associated with reduced risk of cardiovascular events, according to a study published online Dec. 20 in The Lancet.